NovAccess Global Inc. (XSNX)
OTCMKTS · Delayed Price · Currency is USD
0.0005
+0.0004 (400.00%)
Jan 22, 2026, 9:30 AM EST
NovAccess Global Company Description
NovAccess Global Inc., a biopharmaceutical company, engages in the development of novel immunotherapies to treat brain tumor patients in the United States.
It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer.
NovAccess Global Inc. was incorporated in 1997 and is headquartered in New York, New York.
NovAccess Global Inc.
| Country | United States |
| Founded | 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Dwain Morris-Irvin |
Contact Details
Address: 459 Columbus Ave New York, New York 10024 United States | |
| Phone | 213 642 9268 |
| Website | novaccessglobal.com |
Stock Details
| Ticker Symbol | XSNX |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| ISIN Number | US67001N1072 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Dwain K. Morris-Irvin M.P.H., Ph.D. | Chief Executive Officer, Interim Principal Financial Officer and Director |
| Dr. Christopher Wheeler Ph.D. | President of Stemvax Therapeutics |